Revelation Net Income From Continuing Ops from 2010 to 2026
| REVB Stock | USD 2.03 0.13 6.84% |
Net Loss | First Reported 2017-03-31 | Previous Quarter -2.4 M | Current Value -1.9 M | Quarterly Volatility 4.9 M |
Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 42.2 K, Total Revenue of 0.0 or Other Operating Expenses of 5.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.76. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
Revelation | Net Income From Continuing Ops | Build AI portfolio with Revelation Stock |
Analyzing Revelation Biosciences's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Revelation Biosciences's current valuation and future prospects.
Latest Revelation Biosciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Revelation Biosciences over the last few years. It is Revelation Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Revelation Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 2,220,040 | |
| Geometric Mean | 8,396,892 | |
| Coefficient Of Variation | 631.63 | |
| Mean Deviation | 10,694,071 | |
| Median | 4,505,000 | |
| Standard Deviation | 14,022,382 | |
| Sample Variance | 196.6T | |
| Range | 46.7M | |
| R-Value | (0.48) | |
| Mean Square Error | 161.6T | |
| R-Squared | 0.23 | |
| Significance | 0.05 | |
| Slope | (1,329,896) | |
| Total Sum of Squares | 3146T |
Revelation Net Income From Continuing Ops History
About Revelation Biosciences Financial Statements
Revelation Biosciences stakeholders use historical fundamental indicators, such as Revelation Biosciences' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Revelation Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revelation Biosciences' assets and liabilities are reflected in the revenues and expenses on Revelation Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.5 M | -12.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out the analysis of Revelation Biosciences Correlation against competitors. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value—what Revelation Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.